Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5
HOS-086156 · Präparat HOS-083284
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of lovastatin
Inhibitors and simvastatin; thereby, increasing the risk of
myopathy including rhabdomyolysis (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 8b4fbc9131c29d8d54837b6bc1d67e923de97bd04a2bcdfa67759a30175f968e · Zeichen 5998–6372 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 36–37
HOS-086389 · Präparat HOS-083284
36
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of lovastatin
Inhibitors and simvastatin; thereby, increasing the risk of
myopathy including rhabdomyolysis (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 79b680ca1f9438eb58fb277511a5dfe3e5d27ba155522846a806e0460cbe4994 · Zeichen 5795–6170 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 20
HOS-086303 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism,
Pravastatin, Rosuvastatin, Simvastatin such as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent
or as a pharmacokinetic enhancer. Since increased concentrations of lovastatin and
simvastatin may predispose patients to myopathies, including rhabdomyolysis, the
combination of these medicinal products with ritonavir is contraindicated (see
section 4.3). Atorvastatin is less dependent on CYP3A for metabolism. While
rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin
exposure has been reported with ritonavir co-administration. The mechanism of this
interaction is not clear, but may be the result of transporter inhibition. When used
with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the
lowest possible doses of atorvastatin or rosuvastatin should be administered. The
metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and
interactions are not expected with ritonavir. If treatment with an HMG-CoA
reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9aca472a9605d2ce92f2e3c73c3d58774cec61e0cad5a2ae7e9aa807365f0d07 · Zeichen 43147–44996 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086472 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such
Pravstatin, Rosuvastatin, Simvastatin as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as
a pharmacokinetic enhancer. Since increased concentrations of lovastatin and simvastatin
may predispose patients to myopathies, including rhabdomyolysis, the combination of
these medicinal products with ritonavir is contraindicated (see section 4.3). Atorvastatin
is less dependent on CYP3A for metabolism. While rosuvastatin elimination is not
dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with
ritonavir co-administration. The mechanism of this interaction is not clear, but may be
the result of transporter inhibition. When used with ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or
rosuvastatin should be administered. The metabolism of pravastatin and fluvastatin is not
dependent on CYP3A, and interactions are not expected with ritonavir. If treatment with
an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage aecf6db95f104726bea3f53130826841fcecb464a1fff5ff24afdad33e090079 · Zeichen 44359–46167 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-088420 · Präparat HOS-083643
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4
substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) cimetidine (HOS-085835) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage a9f62e8a7a2ad033da44c6ce95edc0d70ca543f35d19c1f112cf9e2ba9a9e339 · Zeichen 6880–7066 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-088453 · Präparat HOS-083643
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4
substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) cimetidine (HOS-085835) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage a9f62e8a7a2ad033da44c6ce95edc0d70ca543f35d19c1f112cf9e2ba9a9e339 · Zeichen 6882–7068 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-088486 · Präparat HOS-083643
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4
substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) cimetidine (HOS-085835) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage a9f62e8a7a2ad033da44c6ce95edc0d70ca543f35d19c1f112cf9e2ba9a9e339 · Zeichen 6881–7067 im Abschnitt
Wechselwirkungen · Arava
Arava 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-089672 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5491–6465 im Abschnitt
Wechselwirkungen · Arava
Arava 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-089736 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5493–6467 im Abschnitt
Wechselwirkungen · Arava
Arava 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-089796 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5489–6463 im Abschnitt
Wechselwirkungen · Prandin
Prandin 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-108648 · Präparat HOS-093055
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4
substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) cimetidine (HOS-085835) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage a9f62e8a7a2ad033da44c6ce95edc0d70ca543f35d19c1f112cf9e2ba9a9e339 · Zeichen 6880–7066 im Abschnitt
Wechselwirkungen · Prandin
Prandin 1 mg tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-108683 · Präparat HOS-093055
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4
substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) cimetidine (HOS-085835) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage a9f62e8a7a2ad033da44c6ce95edc0d70ca543f35d19c1f112cf9e2ba9a9e339 · Zeichen 6881–7067 im Abschnitt
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-108717 · Präparat HOS-093055
Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4
substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) cimetidine (HOS-085835) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage a9f62e8a7a2ad033da44c6ce95edc0d70ca543f35d19c1f112cf9e2ba9a9e339 · Zeichen 6881–7067 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 6
HOS-108817 · Präparat HOS-093083
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of
Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5).
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c938be9b188cbabde88400ddb49de67c2831b955f638dc8fa5306b13f1652968 · Zeichen 6187–9289 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 43
HOS-108989 · Präparat HOS-093083
HMG Co-A Lovastatin, simvastatin Increased plasma concentrations of
Reductase Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5)
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil
in patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f8543c2c8cda6c1a0fcb441c8b738d361d39474d709f5eb46342c2fd917ec3a5 · Zeichen 6637–8576 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 78
HOS-109063 · Präparat HOS-093083
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of
Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy including
rhabdomyolysis (see section 4.5).
Microsomal triglyceride Lomitapide Increased plasma concentrations of
transfer protein (MTTP) lomitapide (see section 4.5).
inhibitor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c1f30e879c14eae663f4c58f72a72fc5a44b4e93e6280c2d524687cb97bb42ed · Zeichen 6506–7088 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 23–24
HOS-108925 · Präparat HOS-093083
23
Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of
increased due to P-glycoprotein, glecaprevir/pibrentasvir and
BCRP and OATP1B inhibition by Kaletra is not recommended due
lopinavir/ritonavir. to an increased risk of ALT
elevations associated with
increased glecaprevir exposure.
Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to
voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and
voxilaprevir may be increased due sofosbuvir/velpatasvir/
to P-glycoprotein, BCRP and voxilaprevir.
OATP1B1/3 inhibition by
lopinavir/ritonavir. However,
only the increase in voxilaprevir
exposure is considered clinically
relevant.
HCV protease inhibitors
Simeprevir 200 mg daily Simeprevir: It is not recommended to
(ritonavir 100 mg BID) AUC: ↑ 7.2-fold co-administer Kaletra and
Cmax: ↑ 4.7-fold simeprevir.
Cmin: ↑ 14.4-fold
Herbal products
St John’s wort (Hypericum Lopinavir: Herbal preparations containing St
perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels.
Lopinavir and ritonavir levels may
increase on stopping
St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra
can be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels
due to CYP3A inhibition by of these products have been
lopinavir/ritonavir. stabilised.
Lipid lowering agents
Lovastatin and Simvastatin Lovastatin, Simvastatin: Since increased concentrations of
Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination
of these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) lovastatin (HOS-086157) pibrentasvir (HOS-086298) lomitapide (HOS-086160) simvastatin (HOS-086158) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) tacrolimus (HOS-085202) velpatasvir (HOS-108929) simeprevir (HOS-086302) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage d661859df9e7416124e84f058321f8363c31c96c6c3cbfadb04946272feb4ff7 · Zeichen 52766–57555 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-109022 · Präparat HOS-093083
59
Herbal products
St John’s wort Lopinavir: Herbal preparations containing St
(Hypericum perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels. Lopinavir
and ritonavir levels may increase on
stopping St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra can
be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors may
concentrations due to CYP3A cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest possible
lopinavir/ritonavir. dose of atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered with
While rosuvastatin is poorly rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin reductase inhibitor is indicated,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 828eb1430737116e7e38afe94ac9495cef2e1489ddb625df82544aac21c48455 · Zeichen 52305–56991 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96
HOS-109101 · Präparat HOS-093083
95
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest
lopinavir/ritonavir. possible dose of atorvastatin should
be administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered
While rosuvastatin is poorly with rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8615aceaaf9aeead58e7d8428a116c5869ad8f9e57e471dff2f6359133eeb12b · Zeichen 55116–58920 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-109934 · Präparat HOS-093279
Simvastatin: Co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma
concentrations of simvastatin (a CYP3A4 substrate) and its active -hydroxy acid metabolite by 34%
and 46%, respectively. The plasma concentrations of bosentan were not affected by concomitant
simvastatin. Monitoring of cholesterol levels and subsequent dosage adjustment should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) cholesterol (HOS-087961) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage e61552011a59d82e1160ea4b8f6c7100809ad1f6ecc47f422b7e2435916462b3 · Zeichen 7072–7459 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.